Cancer treatment–related bone loss: a review and synthesis of the literature

Current Oncology

Volumn 15, Issue S1, 2008, Pages S30-S40

  Khan, M N ^a   Khan, A A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

androgen deprivation; antiresorptive therapy; aromatase inhibition; bisphosphonates; bone loss; Cancer therapy; os teoporosis; osteonecrosis of jaw

Indexed keywords

EID: 51349126647     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2008.174     Document Type: Article

References (87)

1. Khan AA, Hanley DA, Bilezikian JP, et al. Standards for per-forming DXA in individuals with secondary causes of osteoporo-sis. J Clin Densitom 2006;9:47–57.
2. Shapiro CL, Manola J, Leboff M. Ovarian failure after adju-vant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306–11.
3. Garrett TJ, Vahdat LT, Kinne DW. Systemic adjuvant therapy of breast cancer. J Surg Oncol 1997;64:167–72.
4. Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002;20:4628–35.
5. Fogelman I, Blake GM, Blamey R, et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclo-phosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003;14:1001–6.
6. McCloskey E. Effects of third-generation aromatase inhibi-tors on bone. Eur J Cancer 2006;42:1044–51.
7. McCloskey E, Hannon R, Lakner G, Clack G, Miyamoto A, Eastell R. The letrozole (L), exemestane (E) and anastrozole (A) pharmacodynamics (LEAP) trial: a direct comparison to bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women [abstract 555]. Proc Am Soc Clin Oncol 2006;24:.
8. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, on behalf of the ATAC Trialists’ Group. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230). J Bone Miner Res 2006;21: 1215–23.
9. Geisler J, Lønning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomized placebo-controlled study. Eur J Cancer 2006;42: 2968–75.
10. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852–6.
11. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmeno-pausal women. J Clin Oncol 1996;14:78–84.
12. Fisher B, Costantino JP, Wickerman DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–88.
13. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 2005;97:1652–62.
14. Baum M, Buzdar A, Cuzick J, et al. on behalf of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmeno-pausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802–10.
15. Thürlimann B, Keshaviah A, Coates AS, et al. on behalf of the Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353: 2747–57.
16. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154–64.
17. Coombes RC, Hall E, Gibson LJ, et al. on behalf of the Inter-group Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmeno-pausal women with primary breast cancer. N Engl J Med 2004; 350:1081–92.
18. Jakesz R, Jonat W, Gnant M, et al. on behalf of the ABCSG and the GABG. Switching of postmenopausal women with endo-crine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455–62.
19. Lønning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral den-sity, bone biomarkers, and plasma lipids in patients with sur-gically resected early breast cancer. J Clin Oncol 2005;23: 5126–37.
20. Robson M, Dawson N. How is androgen-dependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am 1996;10:727–47.
21. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with syn-thetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219–22.
22. Daniell HW. Osteoporosis after orchiectomy for prostate can-cer. J Urol 1997;157:439–44.
23. Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Bone fractures associated with luteinizing hormone–releas-ing hormone agonists used in the treatment of prostate carci-noma. Cancer 1997;79:545–50.
24. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001;166:1724–8.
25. Verhelst J, Denis L, Van Vliet P, et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 1994;41: 525–30.
26. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004;22:2546–53.
27. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434–41.
28. Brown JP, Josse RG on behalf of the Scientific Advisory Coun-cil of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(suppl):S1–34.
29. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669–83.
30. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 1999;130:431–9.
31. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmeno-pausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87: 3609–17.
32. United States, National Institutes of Health, National Cancer Institute (NCI). Study of Tamoxifen and Raloxifene (STAR) Trial [Web page]. Bethesda, MD: NCI; April 26, 2006. [Available online at: www.cancer.gov/star; cited January 1, 2008]
33. Reszka AA, Rodan GA. Bisphosphonate mechanism of ac-tion. Curr Rheumatol Rep 2003;5:65–74.
34. Meunier PJ, Arlot M, Chavassieux P, Yates AJ. The effects of alendronate on bone turnover and bone quality. Int J Clin Pract Suppl 1999;101:14–17.
35. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with ex-isting vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41.
36. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077–82.
37. Ravn P, Weiss SR, Rodriguez–Portales JA, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 2000;85:1492–7.
38. Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189–99.
39. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485–92.
40. Surrey ES, Voigt B, Fournet N, Judd HL. Prolonged gonadot-ropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone “add-back” therapy. Fertil Steril 1995;63: 747–55.
41. Lindsay R, Adachi JD, Barton IP, Manhart MD. Fracture risk reduction due to antiresorptive treatment is independent of the magnitude of BMD improvement. Arthritis Rheum 2003;48:S84.
42. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–52.
43. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteo-poros Int 2000;11:83–91.
44. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within 6 months. Curr Med Res Opin 2004;20:433–9.
45. Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462–8.
46. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333–40.
47. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr. Risedronate increases bone mass in an early postmeno-pausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998;83:396–402.
48. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-di-mensional microcomputed tomography. Calcif Tissue Int 2003; 73:423–32.
49. Van Poznak C, Hannon RA, Clack G, et al. The SABRE (Study of Anastrozole with the Bisphosphonate Risedronate) study: the effects of risedronate on BMD and bone metabolism in post-menopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer—first results [abstract 021S]. Bone 2007;40(suppl 2):.
50. Russell RG. Bisphosphonates: mode of action and pharma-cology. Pediatrics 2007;119(suppl 2):S150–62.
51. Ringe JD. Zoledronic acid in the treatment of Paget’s disease and other benign bone disorders. Expert Rev Endocrinol Metab 2006;1:15–24.
52. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral den-sity. N Engl J Med 2002;346:653–61.
53. Black DM, Delmas P, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22.
54. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole–induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829–36.
55. Watts N, Freedholm D, Daifotis A. The clinical tolerability profile of alendronate. Int J Clin Pract Suppl 1999;101:51–61.
56. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99–102.
57. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 2005;353:898–908.
58. Hoff AO, Toth B, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy [ab-stract 1218]. J Bone Min Res 2005;20:S55.
59. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115–37.
60. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999;84:3076–81.
61. Cauley JA, Robbins J, Chen Z, et al. on behalf of the Women’s Health Initiative Investigators. Effects of estrogen plus proges-tin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003;290:1729–38.
62. Anderson GL, Limacher M, Assaf AR, et al. on behalf of the Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hys-terectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–12.
63. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668–76.
64. Rosen CJ, Chesnut CH 3rd, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997;82:1904–10.
65. Rossouw JE, Anderson GL, Prentice RL, et al. (Writing Group for the Women’s Health Initiative Investigators). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. Writing Group for the Women’s Health Initiative Investigators. JAMA 2002;288:321–33.
66. United States, Food and Drug Administration (FDA). FDA up-dates hormone therapy information for postmenopausal women [press release]. FDA News February 10, 2004. [Available online at: www.fda.gov/bbs/topics/NEWS/2004/ NEW01022.html; cited December 12, 2007]
67. McClung MR, Leweicki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821–31.
68. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone me-tastases from breast cancer. Clin Cancer Res 2006;12:1221–8.
69. Rubin MR, Cosman F, Lindsay R, Bilezikian JP. The anabolic effects of parathyroid hormone. Osteoporos Int 2002;13: 267–77.
70. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439–46.
71. Seeman E. Reduced bone formation and increased bone re-sorption: rational targets for the treatment of osteoporosis. Osteoporos Int 2003;14(suppl 3):S2–8.
72. Ettinger M, Greenspan S, Marriott T, et al. PTH (1-84) prevents first vertebral fracture in postmenopausal women with os-teoporosis: the TOP study [abstract]. Salt Lake City, UT: NPS Pharmaceuticals; December 2004, as cited in Shrader SP, Ragucci KR. Parathyroid hormone (1-84) and treatment of osteoporosis. Ann Pharmacother 2005;39:1511–16.
73. Lindsay R, Nieves J, Formica C, et al. Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 1997;350:550–5.
74. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001;16:925–31.
75. Black DM, Greenspan SL, Ensrud KE, et al. on behalf of the PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207–15.
76. Tashjian AH Jr, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002;17:1151–61.
77. Ma YL, Bryant HU, Zeng Q, et al. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not re-tarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 2003;144: 2008–15.
78. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121–9.
79. Boivin G, Deloffre P, Perrat B, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res 1996;11:1302–11.
80. Marie PJ. Effects of strontium on bone formation and bone cells. In: Neve J, ed. Therapeutic Use of Trace Elements. New York: Plenum Press; 1996: 277–82.
81. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-rang-ing, placebo-controlled PREVOS trial. Osteoporos Int 2002;13: 925–31.
82. Reginster JY, Meunier PJ. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int 2003;14(suppl 3):S56–65.
83. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060–6.
84. Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-defi-cient rats. J Bone Miner Res 1993;8:607–15.
85. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459–68.
86. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmeno-pausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90: 2816–22.
87. Body JJ, Bergmann S, Boonen S, et al. Management of cancer treatment–induced bone loss in early breast and prostate cancer—a consensus paper of the Belgian Bone Club. Osteoporos Int 2007;18:1439–1450.